50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis
Recommended Citation
McMichael A, Stein-Gold L, Soung J, Kindred C, Choi O, Chan D, Jeyarajah J, Heath CR, Bhutani T, Sauder M, Alexis A. 50532 VISIBLE: Guselkumab Demonstrated Significant Scalp Psoriasis Clearance and Scalp Itch Improvements at Week 16 in Skin of Color Participants With Moderate-to-Severe Plaque Psoriasis. J Am Acad Dermatol 2024; 91(3):AB97.
Document Type
Conference Proceeding
Publication Date
9-1-2024
Publication Title
J Am Acad Dermatol
Abstract
Introduction: Scalp is the most commonly involved special site among patients with moderate-to-severe plaque psoriasis, and may be challenging to treat in skin of color (SoC) patients due to greater visibility of scales and styling/hair types. We report the efficacy of guselkumab (GUS) on scalp psoriasis in the Phase 3b VISIBLE study, which exclusively enrolled SoC participants with moderate-to-severe plaque psoriasis. Methods: VISIBLE Cohort-A (N=103) participants were randomized 3:1 to receive GUS 100mg or placebo(PBO). Scalp psoriasis outcomes (scalp-specific Investigator Global Assessment[ss-IGA] score, Psoriasis Scalp Severity Index[PSSI], scalp surface area[SSA], and scalp itch numeric rating scale[NRS] score) were evaluated at Week(W)16 among participants with at least mild scalp psoriasis (ss-IGA score≥2) at baseline. Results: At baseline, 77 participants had at least mild scalp psoriasis (ss-IGA 2-mild [22.1%], 3-moderate [63.6%], 4-severe [14.3%]; mean SSA 33.4%). Significantly greater improvements in scalp itch NRS were observed in GUS vs PBO groups, respectively (mean change from baseline -4.3 vs -1.3, p<0.001). Significantly greater proportions of participants in GUS vs PBO groups, respectively, achieved: ss-IGA 0/1 with ≥2-grade improvement from baseline (80.7% vs 15.0%, p<0.001); ss-IGA 0 (71.9% vs 10.0%, p<0.001). At W16, mean percent change from baseline in SSA was -87.6% (improved) for GUS vs +167.1% (worsened) for PBO (p<0.01); and mean percent improvement from baseline in PSSI was 81.0% GUS vs 12.1% PBO (p<0.001). Conclusions: After 3 doses, 80% of participants with at least mild scalp psoriasis achieved clear or almost clear scalp psoriasis with GUS, and reported significant improvements in scalp itch.
Volume
91
Issue
3
First Page
AB97
